Prostate Cancer

Patent Issued for Monoclonal Antibodies Binding to Prostate-Specific Membrane Antigen

Published in Cancer Weekly, September 5th, 2000

BZL Biologics Inc., New York, New York, announced that Cornell University in New York was issued U.S. Patent No. 6,107,090 titled "Treatment and Diagnosis of Prostate Cancer.

BZL holds the exclusive worldwide license to this technology from Cornell University. The issued patent claims monoclonal antibodies that bind to the extracellular domain of prostate specific membrane antigen (PSMAext.) on living cells as both therapeutic and diagnostic agents for prostate cancer. These monoclonal antibodies to the extracellular domain of PSMA may be used unmodified or as a targeting antibody for radioisotopes and/or cytotoxic drugs.

According to Dr. Neil...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry